News & Updates
Filter by Specialty:
Shorter treatment regimen feasible for rifampin-resistant TB?
Individuals with rifampin-resistant tuberculosis (RR-TB) may have the option to undergo shorter treatment periods, as findings from the phase II/III TB-PRACTECAL* trial show the noninferiority and superiority of a 24-week, all-oral regimen to standard of care (SoC). It also had a better safety profile than SoC.
Shorter treatment regimen feasible for rifampin-resistant TB?
13 Feb 2023
Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C
Treatment with metformin results in a significant reduction in hepatocellular carcinoma (HCC) incidence following successful antiviral therapy in individuals with diabetes mellitus and chronic hepatitis C (CHC), a recent study has shown.
Metformin lowers HCC risk after antiviral therapy in diabetic patients with hepatitis C
11 Feb 2023
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
The investigational KRAS G12C inhibitor sotorasib appears to be active against previously treated KRAS p.G12C–mutated advanced pancreatic cancer while having an acceptable safety profile, according to the results of a phase I/II trial.
Novel KRAS G12C inhibitor shows promising antitumour activity in mutated pancreatic cancer
11 Feb 2023
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
Patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) exhibited significantly improved progression-free survival (PFS) when treated with lazertinib compared with gefitinib in the first-line setting, results of the LASER301 trial showed.
Is first-line lazertinib monotherapy a potential new SoC for EGFRm NSCLC?
10 Feb 2023
Survival advantage in COVID-19 seen with 8-mg/kg tocilizumab
In the treatment of hospitalized patients with COVID-19, survival outcomes appear to be more favourable with the 8-mg/kg tocilizumab regimen than with the fixed-dose tocilizumab regimen or sarilumab, according to a study.
